This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Intra-Cellular Therapies' Candidate Fails in Phase III Study
by Zacks Equity Research
Intra-Cellular Therapies' (ITCI) lead candidate fails to meet primary endpoint in one of the phase III studies evaluating it in bipolar depression patients. Shares fall.
Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock?
by Zacks Equity Research
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
Implied Volatility Surging for Intra-Cellular (ITCI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Intra-Cellular (ITCI) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock?
by Zacks Equity Research
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
Intra-Cellular Therapies Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Intra-Cellular Therapies has been struggling lately, but the selling pressure may be coming to an end soon.
Options Traders Expect Huge Moves in Intra-Cellular (ITCI) Stock
by Zacks Equity Research
Intra-Cellular (ITCI) needs investors to pay close attention to the stock based on moves in the options market lately.
Company News For Nov 21, 2017
by Zacks Equity Research
Companies In The News are: DY,TWX,RHHBY,ITCI
3 Reasons Why Intra-Cellular Therapies (ITCI) is a Great Momentum Stock
by Zacks Equity Research
Intra-Cellular Therapies (ITCI) is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions.
Why Intra-Cellular (ITCI) Could Be Positioned for a Surge
by Zacks Equity Research
Intra-Cellular (ITCI) has decent short-term momentum and is seeing solid activity on the earnings estimate revision front as well.
Zacks.com featured highlights Summer Infant, Intra-Cellular Therapies, PDL BioPharma, Cogentix Medical and Intrepid Potash
by Zacks Equity Research
Zacks.com featured highlights Summer Infant, Intra-Cellular Therapies, PDL BioPharma, Cogentix Medical and Intrepid Potash
5 Bargain Breakout Stocks Offering Stunning Returns
by Swarup Gupta
The key to this kind of stock selection is to identify players that are trading within a narrow band.
Intra-Cellular (ITCI) Soars: Stock Adds 27.7% in Session
by Zacks Equity Research
Intra-Cellular (ITCI) saw a big move last session, as its shares jumped nearly 28% on the day amid huge volumes.
Are Options Traders Betting on a Big Move in Intra-Cellular (ITCI) Stock?
by Zacks Equity Research
Investors in Intra-Cellular Therapies, Inc. (ITCI) need to pay close attention to the stock based on moves in the options market lately.
Implied Volatility Surging for Intra-Cellular (ITCI) Stock Options
by Zacks Equity Research
Options traders are pricing in a big move for Intra-Cellular (ITCI) shares as it has huge implied volatility.
Can The Uptrend Continue for Intra-Cellular Therapies (ITCI)?
by Zacks Equity Research
Investors certainly have to be happy with Intra-Cellular Therapies, Inc. (ITCI) and its short term performance
5 Cheap Breakout Stocks for Superb Returns
by Swarup Gupta
The technique identifies those stocks whose prices are fluctuating within a specific band.
TESARO Varubi IV Gets Complete Response Letter in the U.S.
by Zacks Equity Research
TESARO (TSRO) announced that it has received a Complete Response Letter from the FDA regarding its NDA for Varubi IV.
Gilead (GILD) HBV Drug Vemlidy Receives European Approval
by Zacks Equity Research
Gilead Sciences (GILD) gained EU approval for Vemlidy for the treatment of chronic HBV infection.
Top Ranked Momentum Stocks to Buy for December 19th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 19th: